-+ 0.00%
-+ 0.00%
-+ 0.00%
ProMIS Neurosciences Licenses Ossianix Brain-Delivery Technology for Alzheimer's Antibody
Share
Listen to the news
ProMIS Neurosciences Licenses Ossianix Brain-Delivery Technology for Alzheimer's Antibody
  • ProMIS Neurosciences licensed Ossianix's TXP1 brain-delivery technology for its PMN310 Alzheimer's antibody.
  • The agreement includes options to extend TXP1 to PMN442 for Parkinson's disease and PMN267 for ALS.
  • Ossianix will receive an upfront payment, with eligibility for development, regulatory and commercial milestones, plus royalties on global net sales.
  • Existing cash will fund short-term obligations; the agreement is not expected to change the projected cash runway through 2027.
  • TXP1 increased antibody delivery to the brain by more than 65-fold in preclinical studies reported by Ossianix.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611170230OMX_____CNEWS_EN_GNW9879045_en) on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending